J&J Medical Device Unit Sales Are 3Q Weak Point -- Market Talk
Dow Jones2026/10/13 10:340633 ET - Johnson & Johnson's medical device business had a rougher quarter relative to the overall company. The drug company logged higher third-quarter sales and raised its outlook for adjusted earnings per share. However, its MedTech business saw sales advance 2.5% to $8.64 billion, below the $8.74 million analysts were expecting, according to FactSet. That was somewhat anemic compared with J&J's pharmaceutical segment, where sales rose 7.7% and beat Wall Street estimates. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
October 13, 2026 06:34 ET (10:34 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Apple’s new CEO shakes things up: Ternus urges Federighi to “boldly develop AI”
Tesla (TSLA.US) drops over 10% in a week, but ARK keeps buying! Cathie Wood: This is the moment we've been waiting for
Despite the recent volatility in Tesla's stock price, ARK Invest founder Cathie Wood, known as the "Goddess of Wall Street," remains optimistic about the company.
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Crypto prices
More
